The Experts below are selected from a list of 141 Experts worldwide ranked by ideXlab platform
Bo L Chawes - One of the best experts on this subject based on the ideXlab platform.
-
efficacy adverse events and inter Drug Comparison of mepolizumab and reslizumab anti il 5 treatments of severe asthma a systematic review and meta analysis
European Clinical Respiratory Journal, 2018Co-Authors: Daniel Pilsgaard Henriksen, Kirsten Sidenius, Ehm A Andersson, Louise Klokker Madsen, Hanne Madsen, Uffe Bodtger, Lars Pedersen, Ole Nørgaard, N Maltbaek, Bo L ChawesAbstract:ABSTRACTBackground: New, complex, and expensive therapies targeting Interleukin-5 (IL-5) to treat severe eosinophilic asthma are emerging.Objective: To assess efficacy, adverse events, and inter-Drug Comparison of mepolizumab and reslizumab for treating severe eosinophilic asthma.Design: A systematic review and meta-analysis on randomized, placebo-controlled, clinical trials elucidating two critical (exacerbation rate and oral corticosteroid (OCS) use) and six important clinical outcomes on the efficacy and safety of mepolizumab and reslizumab.Results: Five studies (N = 2197) contributed with data for exacerbation rate, showing a reduction of 53% (95% CI 46; 59) in favour of anti-IL-5, corresponding to –0.94 annual exacerbations (95% CI –1.08;–0.82), thus exceeding the predefined minimal clinical important difference (MCID) of 25% reduction of the estimated ≥2 annual exacerbations. Quality of evidence was considered moderate, with low heterogeneity in study findings (I2 = 0%). One study (N = 135) contribu...
-
Efficacy, adverse events, and inter-Drug Comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis
European Clinical Respiratory Journal, 2018Co-Authors: Daniel Pilsgaard Henriksen, Kirsten Sidenius, Ehm A Andersson, Louise Klokker Madsen, Hanne Madsen, Uffe Bodtger, Lars Pedersen, Ole Nørgaard, N Maltbaek, Bo L ChawesAbstract:ABSTRACTBackground: New, complex, and expensive therapies targeting Interleukin-5 (IL-5) to treat severe eosinophilic asthma are emerging.Objective: To assess efficacy, adverse events, and inter-Drug Comparison of mepolizumab and reslizumab for treating severe eosinophilic asthma.Design: A systematic review and meta-analysis on randomized, placebo-controlled, clinical trials elucidating two critical (exacerbation rate and oral corticosteroid (OCS) use) and six important clinical outcomes on the efficacy and safety of mepolizumab and reslizumab.Results: Five studies (N = 2197) contributed with data for exacerbation rate, showing a reduction of 53% (95% CI 46; 59) in favour of anti-IL-5, corresponding to –0.94 annual exacerbations (95% CI –1.08;–0.82), thus exceeding the predefined minimal clinical important difference (MCID) of 25% reduction of the estimated ≥2 annual exacerbations. Quality of evidence was considered moderate, with low heterogeneity in study findings (I2 = 0%). One study (N = 135) contribu...
Daniel Pilsgaard Henriksen - One of the best experts on this subject based on the ideXlab platform.
-
efficacy adverse events and inter Drug Comparison of mepolizumab and reslizumab anti il 5 treatments of severe asthma a systematic review and meta analysis
European Clinical Respiratory Journal, 2018Co-Authors: Daniel Pilsgaard Henriksen, Kirsten Sidenius, Ehm A Andersson, Louise Klokker Madsen, Hanne Madsen, Uffe Bodtger, Lars Pedersen, Ole Nørgaard, N Maltbaek, Bo L ChawesAbstract:ABSTRACTBackground: New, complex, and expensive therapies targeting Interleukin-5 (IL-5) to treat severe eosinophilic asthma are emerging.Objective: To assess efficacy, adverse events, and inter-Drug Comparison of mepolizumab and reslizumab for treating severe eosinophilic asthma.Design: A systematic review and meta-analysis on randomized, placebo-controlled, clinical trials elucidating two critical (exacerbation rate and oral corticosteroid (OCS) use) and six important clinical outcomes on the efficacy and safety of mepolizumab and reslizumab.Results: Five studies (N = 2197) contributed with data for exacerbation rate, showing a reduction of 53% (95% CI 46; 59) in favour of anti-IL-5, corresponding to –0.94 annual exacerbations (95% CI –1.08;–0.82), thus exceeding the predefined minimal clinical important difference (MCID) of 25% reduction of the estimated ≥2 annual exacerbations. Quality of evidence was considered moderate, with low heterogeneity in study findings (I2 = 0%). One study (N = 135) contribu...
-
Efficacy, adverse events, and inter-Drug Comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis
European Clinical Respiratory Journal, 2018Co-Authors: Daniel Pilsgaard Henriksen, Kirsten Sidenius, Ehm A Andersson, Louise Klokker Madsen, Hanne Madsen, Uffe Bodtger, Lars Pedersen, Ole Nørgaard, N Maltbaek, Bo L ChawesAbstract:ABSTRACTBackground: New, complex, and expensive therapies targeting Interleukin-5 (IL-5) to treat severe eosinophilic asthma are emerging.Objective: To assess efficacy, adverse events, and inter-Drug Comparison of mepolizumab and reslizumab for treating severe eosinophilic asthma.Design: A systematic review and meta-analysis on randomized, placebo-controlled, clinical trials elucidating two critical (exacerbation rate and oral corticosteroid (OCS) use) and six important clinical outcomes on the efficacy and safety of mepolizumab and reslizumab.Results: Five studies (N = 2197) contributed with data for exacerbation rate, showing a reduction of 53% (95% CI 46; 59) in favour of anti-IL-5, corresponding to –0.94 annual exacerbations (95% CI –1.08;–0.82), thus exceeding the predefined minimal clinical important difference (MCID) of 25% reduction of the estimated ≥2 annual exacerbations. Quality of evidence was considered moderate, with low heterogeneity in study findings (I2 = 0%). One study (N = 135) contribu...
José Dalmau - One of the best experts on this subject based on the ideXlab platform.
-
Drug-induced sleep endoscopy: a two Drug Comparison and simultaneous polysomnography
Sleep Medicine, 2013Co-Authors: Marina Carrasco, Gabriela Agostini, Adelaida Rodrigo, Pau Giner, Fernando Gómez, José DalmauAbstract:Introduction When CPAP intolerance is present in obstructive sleep apnea (OSA) patients, the assessment of pharyngeal obstruction areas is critical in order to increase surgical success rate. Drug-induced sleep endoscopy (DISE) allows visual pharynx evaluation of patients under sedation, artificially reproducing natural sleep. Although consensus has not yet been established on the sedation method, propofol and midazolam are the Drugs most frequently used. The object of the present study is to compare pharyngeal and polysomnographical (PSG) findings during DISE performed either with propofol or midazolam as a single sedative in the same patient. Materials and methods Sixteen patients with sleep breathing disorders were sedated and endoscopically evaluated, under propofol sedation first, followed by midazolam, after confirmation of complete arousal. Simultaneous PSG was performed during sedation. Comparison of pharyngeal obstruction and vibration sites under each of the Drugs is performed using the VOTE classification. PSG findings were also compared. Results There were 15 men and one woman; mean age 42.7 years old, mean body mass index (BMI) 26.9 Kg/m2. Average DISE duration was 20 min with Propofol and 14.3 min with Midazolam. The induced-sleep stage obtained was N2 with both Drugs. There was a good correlation between DISE results with both Drugs (p 0.001). A high level of agreement was found when evaluating tongue base and epiglottic collapse (97% and 87% respectively), and lower at the vellum (84.4%). There was a good correlation of the AHI and minimal O2 saturation with both Drugs. (ICC 0.7 and 0.67). Conclusion A high level of agreement is found when DISE is performed with propofol and midazolam, under continuous perfusion. Acknowledgement To Juan Vinoles.
-
DISE: A 2-Drug Comparison and Simultaneous Polysomnography
Otolaryngology–Head and Neck Surgery, 2012Co-Authors: Marina Carrasco, Gabriela Agostini, Adelaida Rodrigo, Pau Giner, Fernando Gómez, José DalmauAbstract:Objective: The aim of this study is to evaluate propofol and midazolam as sleep inducers in Drug-induced sleep endoscopy, for the topographic diagnosis of upper airway obstruction during sleep; compare one to the other as well as with natural sleep polysomnography results.Method: Prospective series of 16 patients with suspected obstructive sleep apnea. Following physical examination and conventional polysomnography, sleep nasendoscopy along with simultaneous polysomnography was performed, obtaining apnea-hypopnea index, lowest oxygen saturation, apnea durations, and sleep cycle stages. The procedure was done with propofol and with midazolam.Results: There were 15 men and 1 woman; the mean age was 42.7 years old, mean body mass index 26.86. Average Drug-induced sleep endoscopy (DISE) duration was 20 minutes with propofol and 14.3 minutes with midazolam. The induced-sleep stage obtained was of phase 2. On 12 of the patients a whole-night polysomnography study was performed and compared with sleep nasendosco...
N Maltbaek - One of the best experts on this subject based on the ideXlab platform.
-
efficacy adverse events and inter Drug Comparison of mepolizumab and reslizumab anti il 5 treatments of severe asthma a systematic review and meta analysis
European Clinical Respiratory Journal, 2018Co-Authors: Daniel Pilsgaard Henriksen, Kirsten Sidenius, Ehm A Andersson, Louise Klokker Madsen, Hanne Madsen, Uffe Bodtger, Lars Pedersen, Ole Nørgaard, N Maltbaek, Bo L ChawesAbstract:ABSTRACTBackground: New, complex, and expensive therapies targeting Interleukin-5 (IL-5) to treat severe eosinophilic asthma are emerging.Objective: To assess efficacy, adverse events, and inter-Drug Comparison of mepolizumab and reslizumab for treating severe eosinophilic asthma.Design: A systematic review and meta-analysis on randomized, placebo-controlled, clinical trials elucidating two critical (exacerbation rate and oral corticosteroid (OCS) use) and six important clinical outcomes on the efficacy and safety of mepolizumab and reslizumab.Results: Five studies (N = 2197) contributed with data for exacerbation rate, showing a reduction of 53% (95% CI 46; 59) in favour of anti-IL-5, corresponding to –0.94 annual exacerbations (95% CI –1.08;–0.82), thus exceeding the predefined minimal clinical important difference (MCID) of 25% reduction of the estimated ≥2 annual exacerbations. Quality of evidence was considered moderate, with low heterogeneity in study findings (I2 = 0%). One study (N = 135) contribu...
-
Efficacy, adverse events, and inter-Drug Comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis
European Clinical Respiratory Journal, 2018Co-Authors: Daniel Pilsgaard Henriksen, Kirsten Sidenius, Ehm A Andersson, Louise Klokker Madsen, Hanne Madsen, Uffe Bodtger, Lars Pedersen, Ole Nørgaard, N Maltbaek, Bo L ChawesAbstract:ABSTRACTBackground: New, complex, and expensive therapies targeting Interleukin-5 (IL-5) to treat severe eosinophilic asthma are emerging.Objective: To assess efficacy, adverse events, and inter-Drug Comparison of mepolizumab and reslizumab for treating severe eosinophilic asthma.Design: A systematic review and meta-analysis on randomized, placebo-controlled, clinical trials elucidating two critical (exacerbation rate and oral corticosteroid (OCS) use) and six important clinical outcomes on the efficacy and safety of mepolizumab and reslizumab.Results: Five studies (N = 2197) contributed with data for exacerbation rate, showing a reduction of 53% (95% CI 46; 59) in favour of anti-IL-5, corresponding to –0.94 annual exacerbations (95% CI –1.08;–0.82), thus exceeding the predefined minimal clinical important difference (MCID) of 25% reduction of the estimated ≥2 annual exacerbations. Quality of evidence was considered moderate, with low heterogeneity in study findings (I2 = 0%). One study (N = 135) contribu...
Lars Pedersen - One of the best experts on this subject based on the ideXlab platform.
-
efficacy adverse events and inter Drug Comparison of mepolizumab and reslizumab anti il 5 treatments of severe asthma a systematic review and meta analysis
European Clinical Respiratory Journal, 2018Co-Authors: Daniel Pilsgaard Henriksen, Kirsten Sidenius, Ehm A Andersson, Louise Klokker Madsen, Hanne Madsen, Uffe Bodtger, Lars Pedersen, Ole Nørgaard, N Maltbaek, Bo L ChawesAbstract:ABSTRACTBackground: New, complex, and expensive therapies targeting Interleukin-5 (IL-5) to treat severe eosinophilic asthma are emerging.Objective: To assess efficacy, adverse events, and inter-Drug Comparison of mepolizumab and reslizumab for treating severe eosinophilic asthma.Design: A systematic review and meta-analysis on randomized, placebo-controlled, clinical trials elucidating two critical (exacerbation rate and oral corticosteroid (OCS) use) and six important clinical outcomes on the efficacy and safety of mepolizumab and reslizumab.Results: Five studies (N = 2197) contributed with data for exacerbation rate, showing a reduction of 53% (95% CI 46; 59) in favour of anti-IL-5, corresponding to –0.94 annual exacerbations (95% CI –1.08;–0.82), thus exceeding the predefined minimal clinical important difference (MCID) of 25% reduction of the estimated ≥2 annual exacerbations. Quality of evidence was considered moderate, with low heterogeneity in study findings (I2 = 0%). One study (N = 135) contribu...
-
Efficacy, adverse events, and inter-Drug Comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis
European Clinical Respiratory Journal, 2018Co-Authors: Daniel Pilsgaard Henriksen, Kirsten Sidenius, Ehm A Andersson, Louise Klokker Madsen, Hanne Madsen, Uffe Bodtger, Lars Pedersen, Ole Nørgaard, N Maltbaek, Bo L ChawesAbstract:ABSTRACTBackground: New, complex, and expensive therapies targeting Interleukin-5 (IL-5) to treat severe eosinophilic asthma are emerging.Objective: To assess efficacy, adverse events, and inter-Drug Comparison of mepolizumab and reslizumab for treating severe eosinophilic asthma.Design: A systematic review and meta-analysis on randomized, placebo-controlled, clinical trials elucidating two critical (exacerbation rate and oral corticosteroid (OCS) use) and six important clinical outcomes on the efficacy and safety of mepolizumab and reslizumab.Results: Five studies (N = 2197) contributed with data for exacerbation rate, showing a reduction of 53% (95% CI 46; 59) in favour of anti-IL-5, corresponding to –0.94 annual exacerbations (95% CI –1.08;–0.82), thus exceeding the predefined minimal clinical important difference (MCID) of 25% reduction of the estimated ≥2 annual exacerbations. Quality of evidence was considered moderate, with low heterogeneity in study findings (I2 = 0%). One study (N = 135) contribu...
